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Background: After intravenous injection, the photosensitizer dihematopor- 
phyrin ether is selectively retained in tumor cells. This photosensitizer 
absorbs 630 nm wavelength light energy and produces a singlet oxygen that 
destroys the tumor. Photodynamic therapy was performed on endobron- 
chial tumors with the use of light generated by an argon dye laser system 
delivered through cylinder diffusing tip quartz fibers passed through the 
biopsy channel of a flexible endoscope. Objectives: Our objectives were to 
determine factors affecting survivals, benefits, and complications. Methods: 
From 1982 to May 1996, photodynamic therapy was performed on 175 
patients with endobronchial tumors. Sixteen had stage I disease, 9 stage II, 
42 stage IIIA, 64 stage IIIB, and 44 stage IV. All were followed up until 
death or November 1996. Results: Multivariate analysis of survival of the 
effects of age, sex, race, histologic features, Karnofsky Performance Status, 
and clinical stage showed the clinical stage (p < 0.0001) to be the most 
statistically significant factor. Sixteen patients with stage I disease had a 
93% 5-year disease-related stimated survival. Median (months) survivals 
were as follows: stage I = not reached; stage II = 22.5; stage IIIA = 5.7; 
stage IIIB = 55; and stage IV = 5.0. Performance status does become 
significant when it reaches 50 but was not significant for stages I or II. 
Conclusions: Photodynamic therapy may be considered as an alternative 
treatment for patients under consideration for surgical treatment for stage 
I carcinoma in whom the risk of surgery is high. The length of palliation for 
patients with noncurative disease was equal to or better than that reported 
historically for most other treatment regimens. (J Thorac Cardiovasc Surg 
1997;114:940-7) 
T he use of selective photodynamic therapy (PDT) to treat patients with malignant umors is based 
on three observations: (1) after being injected intra- 
venously, the photosensitizer disseminates to all 
cells; (2) owing to differences in vascular and lym- 
phatic clearance from tumors and retention of the 
photosensitizer by the tumor cells, the photosensi- 
tizer is selectively retained in the tumor cells and 
interstitial tissue of the tumor, so that after 2 days 
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there is a greater concentration of the photosensi- 
tizer in the tumors than in the adjacent normal 
tissue; (3) the photosensitizer will absorb light en- 
ergy and produce singlet oxygen, which destroys the 
tumor. Because there is less photosensitizer in the 
adjacent issue, it will react less. We report here our 
experience using PDT to treat patients with primary 
endobronchial and tracheal adenocarcinoma and 
squamous cancer. 
A limiting factor in the effectiveness of PDT as 
currently performed is the fact that the light pene- 
trates only 5 to 10 ram. The bronchi, however, have 
a maximum diameter of 10 mm and therefore PDT 
is ideally suited to relieving obstruction resulting 
from endobronchial tumors. 
Patients and methods 
In a prospective study from 1982 to May 1996, we used 
PDT to treat 175 patients with primary endobronchial or
tracheal carcinoma nd evaluated their survival up to 
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November 1996. Entry criteria were a histologic diagnosis 
of adenocarcinoma or squamous cell carcinoma nd fail- 
ure of conventional treatment, ineligibility for them be- 
cause of medical status, or patient refusal. Follow-up was 
100%. One hundred seven patients were white men, 52 
white women, 12 black men, three black women, and one 
Hispanic woman. Seventeen had adenocarcinoma and 158 
squamous carcinoma. Their ages ranged from 35 to 97 
years with a mean and median of 65 years. One hundred 
twenty-eight ad had unsuccessful conventional therapies 
(chemotherapy and/or surgery, and/or external radiation 
or brachyradiation, and/or yttrium-aluminum-garnet 
[YAG] laser). Forty-seven had no previous treatment. 
All patients igned an informed consent form as part of 
a protocol approved by the Institutional Review Board of 
the Grant Laser Center, and their disease was clinically 
staged at the time of the PDT according to the TNM 
system 1 based on the history, physical examination, bron- 
choscopic findings, and computed tomographic scans of 
the chest and abdomen. Sixteen patients had stage I 
disease (all squamous), 9 stage II (all squamous), 42 stage 
I I IA (3 adenocarcinoma, 39 squamous), 64 stage IIIB (7 
adenocarcinoma, 57 squamous), and 44 had stage IV 
disease (7 adenocarcinoma, 37 squamous). 
Three other patients with squamous cell carcinoma-in- 
situ of the endobronchial tree were also treated. 
PDT was performed with 630 nm light generated by an 
argon dye laser system (Spectra Physics, Mountain View, 
Calif.) as the activator delivered through cylinder diffusing 
tip quartz fibers passed through the biopsy channel of a 
flexible endoscope. These 0.5 to 2.5 cm diffuser tips are 
modified to deliver the light 360 degrees radially. When 
possible, the diffuser tip was inserted into the tumor 
(interstitial treatment). However, it usually was placed 
alongside the tumor (surface treatment). 
Initial treatments were performed with hematoporphy- 
rin derivative as the photosensitizer, but for the past 12 
years we have used the more purified form dihematopor- 
phyrin ether (DHE) (Quadra Logic Technologies, Van- 
couver, B.C., Canada) injected intravenously. 
Various photosensitizer doses, day of treatment after 
injection, light power densities, and light doses were 
evaluated. 2-4 Analyses of the results from these various 
parameters led us to now use 60 mg of DHE per meter 
squared of body surface. Initially PDT was performed 2
days after the injection, but for the past 7 years we have 
been treating patients on the same day as the injection, 
injecting in the morning and doing the bronchoscopic 
treatment and PDT in the afternoon. PDT can be done as 
soon as 10 minutes or as late as 7 days after injection of 
the sensitizer, s At the end of the treatment we mechani- 
cally remove as much of the tumor as possible with forceps 
and snares. This is an integral part of the treatment for 
obstructive lesions but not for superficial lesions. After 
PDT the tumors can be removed mechanically without 
fear of excessive bleeding. Fogarty catheters and arterial 
balloons are used to dilate bronchi and remove tumor and 
any blood clots if needed. 
For several years we used power densities of 500 mW 
per centimeter of diffusing fiber (mW/CF); however, 
manufacturer's modifications of the fibers now cause them 
to burn off at this power. Therefore we now use 400 
mW/CF. Light doses are 400 joules per centimeter of 
diffusing fiber (J/CF) for trachea and main bronchi; 300 
J/CF for lobar bronchi, and 200 J/CF for segmental 
bronchi. 
Toilet bronchoscopic treatments are done 1 day and 3 
days after PDT. These are essential treatments and must 
be done to remove exudate and secretions. If residual 
viable tumor is found at the first toilet bronchoscopy we 
retreat his site. This can usually be determined clinically 
by blood oozing from the sites after tumor removal. The 
reacted tumor does not bleed. 
We now use light general anesthesia almost exclusively 
for the bronchoscopic treatment, regardless of the pa- 
tient's respiratory status. It is important o keep the 
anesthetist aware of how much time will be needed for the 
procedure to permit extubation at the end of the bron- 
choscopic treatment or in the recovery room. We do not 
use narcotics. The arterial oxygen saturation and expired 
carbon dioxide level are continuously monitored, and 
during the treatment the inspired oxygen fraction is kept 
below 40%. If the patient's oxygen saturation falls below 
90% we Stop the treatment, ventilate with 100% oxygen 
until adequate saturation is obtained, and then drop the 
inspired oxygen fraction to 40% and continue the treat- 
ment. The standard flexible bronchoscope, lubricated with 
silicone, is passed through an 8.5 mm endotracheal tube. 
We have not used a rigid bronchoscope for 10 years. 
One month after PDT a repeat endoscopic examination 
was done, and residual tumor was treated after another 
injection of photosensitizer. Patients were then periodi- 
cally subjected to endoscopic examination and treated 
again for symptomatic residual tumor. Two hundred 
ninety-five injections of photosensitizer were made (mean 
1.7 per patient) and 492 PDT bronchoscopic treatments 
were performed (mean 2.8 per patient). Eleven hundred 
twenty-eight treatments were done to 673 different sites. 
The clinical stage of disease, Karnofsky Performance 
Status (KPS), 6 weight, diet, and ordinal scaled levels of 
pain, dyspnea, oxygen requirement, hemoptysis, and 
cough were recorded at each endoscopic examination. 
Biopsy specimens and brushings were taken at each 
endoscopic study. At the beginning and end of each 
bronchoscopic treatment the minimal diameter open and 
the percent of obstruction were estimated by using biopsy 
forceps, the known diameter of the bronchoscope, and 
photographs. Complications, the color and consistency of 
the tumor, and the amount of edema, exudate, bleeding, 
and mucositiS were evaluated and recorded by means of 
ordinal scales. 
The survival status or time and cause of death were 
verified by direct communication with the patient or 
family and the primary physician. 
No patients were refused treatment because of a low 
KPS. Frequently their poor status was due to an obstruc- 
tive lesion and if it could be i'emoved their condition could 
be improved. 
Statistical analyses were performed with the use of 
SuperANOVA, StatView, and Survival Tools (Abacus 
Concepts, Inc., Berkeley, Calif.). Disease-specific survival 
times in months were calculated from the time of their 
first treatment to the end point of November 1996 by 
means of Kaplan-Meier tables and curves. The Breslow- 
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Fig. 1. Kaplan-Meier cumulative survival curves for patients with endobronchial carcinoma treated with 
PDT stratified by their clinical stage at the time of PDT. 
Gehan-Wilcoxon test was used to compare the signifi- 
cance of differences of survival distributions because it is 
more likely to detect early differences than log-rank tests 
and most of the deaths occur early in all series of 
endobronChial cancer. Cox proportional hazards tests 
were used to estimate the effects of different variabies on 
the length of survival. All statistics used 95% confidence 
limits. 
Results 
The effect of different variables on survival of 175 
patients with adenocarcin0ma or squamous carcinoma 
after PDT was estimated by means of multivariate 
analysis. A model of the effects of age (p = 0.599), sex 
(p = 0.923), race (p = 0.903), KPS (p = 0.013), 
histologic haracteristics (p = 0.301), and clinical stage 
showed that the most statistically significant variable 
was the stage (p = 0.0001). The global likelihood ratio 
for the model was significant (p < 0.0001). 
The median survival of all patients was 7 months 
(mean = 18.6 months). Median survivals stratified 
by clinical stage in months were as follows: stage I = 
not reached; stage I I  --- 22.5; stage I I IA= 5.7; stage 
I I IB  = 5.5, and stage IV = 5. Mean survivals 
stratified by clinical stage were as follows: stage I = 
63; stage I I  = 39; stage I I IA= 11; stage I I IB  = 12, 
and stage IV = 8. 
When split by KPS, there is a significant differ- 
ence in the survival, but the KPS does not become 
significant until it falls below 50 and is not significant 
for stages I or II. For stage I I IA  the median survival 
was 8.2 months when the KPS was greater than 50 
and 2.0 for a KPS less than 50. For stage I I IB  the 
median survival was 7.2 months when the KPS was 
more than 50 and 4.0 for a KPS less than 50. For 
stage IV survival was 6.5 months when the KPS was 
greater than 50 and 2.6 for a KPS less than 50. 
Thirty-two (21%) of 150 patients with Stage I I I  or 
IV disease survived 12 months or more, and six of 
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Table I. Patients who died within 30 days of first treatment 
Oxygen l~spnea Months 
Hemoptysis requirement level .Age after 
Cause of death grade grade grade KPS Stage Histology (yr) Sex Race treatment 
Pulmonary hemorrhage 2 1 2 60 IIIA SQ 55 M W 0.8 
Pulmonary hemorrhage 2 2 4 30 IIIB SQ 75 M W 0.8 
Pulmonary hemor- 3 2 2 50 IIIB SQ 75 M B 0.5 
rhage, abscess cavity 
Pulmonary hemorrhage 3 0 2 70 IV SQ 62 M B 0.8 
Stroke, respirator, ex- 0 0 1 70 IIIB SQ 76 M W 0.8 
tubated per family 
Pneumonia, renal fail- 0 2 4 40 IIIA SQ 70 M W 0.5 
ure sepsis 
Pneumonia, respirator, 0 2 4 30 IIIA SQ 60 M W 0.3 
extubated per family 
Dead Of disease 0 2 4 20 IliA AD 60 F W 0.8 
these had a KPS less than 50. Patients who survived 
more than 12 months are listed by clinical stage: 
Stage IIIA: 12, 14, 16, 17, 18, 27, 34, 35, 53, 69 
months 
Stage IIIB: 13, 14(4), 15, 17, 18, 19, 23, 26, 28, 29, 30, 
32, 53 months 
Stage IV: 12(2), 21, 24, 35, 37 months 
When clinical stages IIIA, IIIB, and IV were 
analyzed as a separate subgroup, the multivariate 
analysis showed the KPS (p = 0.0102) statistically 
more significant han the stage (p = 0.3071). Also, 
Breslow-Gehan-Wilcoxon a alysis of Kaplan-Meier 
survival curves for the subgroup stages IIIA, IIIB, 
and IV was significant for grouping by KPS (p = 
0.0001) but not significant for grouping by clinical 
stage (p = 0.292). Fig. 1 shows the Kaplan-Meier 
survival estimates for patients with endobronchial 
tumor stratified by clinical stage. 
Three patients with squamous cell carcinoma in 
situ had complete responses with no evidence of 
recurrence at 8, 74, and 121 months. 
Sixteen patients had clinical stage I disease. All 
were deemed medically ineligible for surgery by 
thoracic surgeons. The estimated isease-related 
5-year survival for all patients with stage I disease 
was 93%. Eleven are still alive with no evidence of 
disease a median of 29 months (mean 37 months) 
after their first treatment. Two died of their 
disease (one of pulmonary hemorrhage at 9 
months and one of brain metastases at 67 
months). Three Other patients died of unrelated 
diseases (one at 11.7 months of emphysema nd 
congestive heart failure, one at 12.5 months of a 
myocardial infarction, and one of a stroke at 27.5 
months). 
Complications. There were no intraoperative 
deaths during PDT. 
Eight patients died within 30 days of their first 
PDT treatment (4%). Four had stage IIIA disease, 
three stage IIIB, and one stage IV. Their median 
KPS was 45 (mean 46) and median age was 65 years 
(mean 67 years). The causes and time of these 
deaths and their pretreatment conditions are listed 
in Table I. 
While we were delivering oxygen down the 
fiberoptic bronchoscope during a treatment with a 
cylinder fiber in one of our first patients, the fiber 
broke and the oxygen ignited the end of the 
bronchoscope. The patient had no serious conse- 
quences. Since then we have maintained the in- 
spired oxygen fraction below 40% during the 
treatment. PDT causes an edematous and exuda- 
tive reaction, which may completely obstruct a 
major airway. One patient treated by insertion of 
a straight-tip fiber into a retrotracheal tumor 
invading the trachea had a tracheoesophageal 
fistula 1 week after PDT. After repeated treat- 
ments, several patients had strictures completely 
obstructing bronchi with scar tissue that showed 
no evidence of tumor on biopsy, brushing, and 
washings for cytologic examination. Solar photo- 
sensitivity of the skin may last for up to 8 weeks 
after the injection of DHE. 
Discussion 
From treating and monitoring these patients with 
a br0nchoscope, it became obvious that many pa- 
tients die and suffer, not because they have lung 
cancer in the parenchyma, lymph nodes, or extratho- 
racic metastases, but because of the obstruction of 
bronchi or contiguous bronchi leading to lung tissue 
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Table II. Lung cancer median survival in months 
Clinical stage Mountain e (S) Bulzebruck 9 (S) Rosenthaf ° (X) PDT PDT (KPS >- 50) PDT (KPS < 50) 
I 48 38 19 Not reached Not reached NA 
!I 18 17 18 22.5 22.5 NA 
IIIA 12 12 12 6 8 2 
IIIB 7 8 10 6 7 4 
IV 4 6 - -  5 7 3 
S, Surgery; X, x-ray therapy; NA, not applicable. 
that does not have cancer in it per se, or by bleeding 
or sepsis or a combination of these. We strongly 
disagree with investigators who have not used laser 
therapy when they have found the lesion was "too 
small" or the patient did not have symptoms. If 
anything, we have regretted not readministering 
bronchoscopic treatments sooner before the tumor 
spread to other bronchi or became large and bloody. 
The intraoperative and perioperative risk of compli- 
cations of  therapy are much greater for the patient 
who has almost complete obstruction of bronchi on 
which he is dependent for aeration than when the 
bronchi are not as obstructed or the tumor is 
confined to one bronchus. As tumors enlarge, so 
does their blood supply, as well as the length of time 
required for the endoscopic treatment. It is better to 
treat patients when the lesion is small and every few 
months than to wait until the patient is dying. 
Also, there is a benefit to delaying the central 
endobronchial spread of the tumor. The patient 
should be treated even if the tumor is large and the 
distal bronchus cannot be opened. Although the 
tumor obstructing the bronchus may be only a small 
part of the tumor, frequently this is causing the 
symptoms. Patients have maintained a KPS of 90 for 
5 years with repeated bronchoscopic PDT. 
The most significant variable affecting the length 
of survival in our series was the stage of the disease. 
When staged, there was no statistically significant 
difference related to age, sex, or race. 
There was no statistically significance difference 
in the survival distributions within each stage be- 
tween adenocarcinoma and squamous cell carci- 
noma. However, within stages IIIA, IIIB, and IV, a 
KPS above or equal to 50 was a significant favorable 
prognosticator and should be considered in compa r - 
ing survivals from different reatment regimens for 
these stages. The significance of KPS on survival of 
the individual patient, however, depends on the 
cause of the decreased performance. If it is due to 
endobronchial obstruction causing dyspnea, bleed- 
ing, or pneumonia, the condition of these patients 
can be greatly improved by removing the obstruc- 
tion or Stopping the bleeding. Patients with a KPS of 
30 survived 16 (IliA), 32 (IIIB), 35 (IIIA), and 37 
(IV) months. Two patients with a KPS of 40 survived 
12 (IV) and 17 (IIIB) months. 
ComParison of survival after PDT with other 
treatment regimens. Flehinger, Kimmel, and Mel- 
amed 7evaluated the survival of patients with clinical 
stage I non-small-cell ung cancer who refused or 
were considered medically ineligible for surgical 
treatment (n = 92) compared with those who were 
treated surgically (n = 434). The 5-year cumulative 
survival probability after surgery was 62% at Sloan- 
Kettering, 53% at Johns Hopkins, and 52% at the 
Mayo Clinic, and the 5-year survival probability for 
patients not treated surgically was 0% to 7%. The 
5-year disease-related survival after PDT for 16 
patients with stage I carcinoma of the endobronchus 
is estimated to be 93%. Table II compares the 
median survival after PDT by stage with the survival 
after surgical therapy, as reported by Mountain s and 
Bulzebruck and associates, 9 or irradiation, as re- 
ported by Rosenthal and colleagues. 1°
From an analysis of PDT and YAG laser treat- 
ment bronchoscopies, we 11 found no statistically 
significant difference in the mean time required for 
the treatments or in the change in the arterial blood 
pH, carbon dioxide tension, or oxygen tension as 
measured in the recovery room after treatment. 
Analysis of the time after treatment required for 
reobstruction of the bronchus after PDT versus 
YAG laser showed the YAG laser reduced the 
amount of obstruction more at the end of treatment 
than PDT. However, after toilet bronchoscopy of 
the PDT-treated sites, the degree of obstruction was 
essentially the same, and the sites treated with the 
YAG laser became reobstructed faster than the 
PDT-treated sites when compared 2 and 4 weeks 
after treatment. I2 
The fiber for PDT can be inserted blindly into the 
tumor for treatment without fear of burning a hole 
into an adjacent vessel. Endobronchial smoke is 
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always produced with the YAG laser, but not with 
PDT. We have never been able to get a complete 
response using the YAG laser alone. 
Post-PDT pulmonary hemorrhage. Four of the 
178 patients died of pulmonary hemorrhage within 
30 days of PDT. All had hemoptysis with clots 
before treatment. Balchum and Doiron 13 reported 
that four of 35 patients with endobronchial tumor 
and severe hemoptysis before treatment died of 
pulmonary hemorrhage 4 to 5 weeks after PDT. 
Other techniques for management of endobronchial 
tumors are also followed by posttreatment death 
from pulmonary hemorrhage: after brachytherapy, 
four of 56 patients as reported by Macha and 
associates 14 and seven of 18 patients as reported by 
MarshlS; after YAG laser: three of 27 patients as 
reported by Gelb and Epstein 16 and three of 30 
patients as reported by Brutinel and colleagues. 17
This complication may be related to the natural 
history of the disease. Many patients are referred to 
us for the problem of previous massive pulmonary 
bleeding. 
Photosensitizer dosage: milligrams per kilogram 
or milligrams per square meter of body surface? 
The effect of different variables on the percentage 
decrease of primary endobronchial obstruction ob- 
tained with PDT was evaluated in 195 treatments. 18 
There were no statistically significant differences in
the percent decrease of obstruction of the bronchus 
when 1, 1.5, or 2 mg/kg were used as the parameters. 
However, when the quartiles of milligrams per 
square meter were used as parameters, there was a 
significant difference between the results obtained, 
comparing the low with the inner quartiles (p = 
0.0433) and the inner with the high quartiles (p = 
0.0007). The regression curve for the effect of the 
milligrams per square meter showed a peak de- 
crease in the amount of obstruction at 60 mg/m 2(a 
mean of 1.4 mg/kg). This is the drug dose we now 
use .  
Indications for PDT. PDT is ideally suited to 
relieving endobronchial obstructions caused by any 
tumors. All histologic types of endobronchial tumor 
(primary or metastatic) responded to PDT. PDT can 
improve or delay progression of tumor and symp- 
toms such as bleeding, secretions, and dyspnea nd 
thereby improve the quality of life and increase 
survival time. Many patients die of their local dis- 
ease long before they would have died of metasta- 
ses. Survivals of patients with carcinoma-in-situ and 
stage ! disease appear to be as good as those 
historically reported for surgical treatment. Corn- 
plete responses of Tis and stage I endobronchial 
cancers treated with only one PDT have lasted up to 
7 years. Randomized clinical trials should be used to 
compare the effectiveness of PDT versus surgical 
therapy in early-stage lung cancer or to compare 
PDT versus chemotherapy and radiation for pa- 
tients who are ineligible for surgery. 
Hayata and colleagues 19 have preoperatively 
treated patients with PDT to convert hem from 
inoperable to operable candidates. We treated a 
patient with bilateral synchronous tumors by first 
performing a right upper lobectomy for the larger 
adenocarcinoma. Several months later, we treated 
the squamous carcinoma-in-situ in the left upper 
lobe with PDT. If PDT had not been available, the 
operation would not have been done because his 
pulmonary function would not permit bilateral re- 
sections. He has no evidence of disease 121 months 
after PDT. 
Recurrences in bronchial stumps are excellent 
tumors to treat with PDT because there is little 
chance for complication from exudate. Historically, 
the mean survival for patients with bronchial stump 
recurrence is 9 months. 2° We have been able to keep 
some of these patients alive and functioning for 5 
years by repeated bronchoscopic treatments and 
treatments of recurring disease. Often, our goal 
cannot be to improve the patient's condition, but 
only to delay its deterioration. PDT enables destruc- 
tion of the invisible submucosal tumors that will 
grow proximally and obstruct other bronchi. De- 
bulking and decreasing tumor burden before irradi- 
ation or chemotherapy can improve respiratory 
function sooner. 
PDT causes thrombosis of small vessels and often 
can be used to control bleeding from them regard- 
less of their location or cause. The scaled amount of 
bleeding was recorded before, during, and at the 
end of PDT at 283 consecutive bronchoscopic PDTs. 
According to Student's t test, there was a significant 
decrease in the bleeding during and at the end of 
PDT compared with before PDT (p < 0.001). We 
used PDT to treat hree patients with uncontrollable 
class 3 or 4 hemoptysis from nonmalignant lesions. 
There has been no recurrence of hemoptysis at5, 13, 
and 17 months after PDT. 21 PDT stopped life- 
threatening hemoptysis n a patient with hereditary 
telangiectasia after conventional therapies failed. 
He had no bleeding for 26 months after his first 
treatment and has had no bleeding for 41 months 
after a second PDT treatment for recurrence of 
bleeding. 22 
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Discussion 
Dr. Douglas E. Wood (Seattle, Wash.). I congratulate 
the authors on their superb results using endobronchial 
PDT for primary endobronchial nd tracheal carcinoma. 
This series of 175 patients is the largest series in the 
United States and rivals the Japanese xperience in this 
arena. 
The authors' conclusions that survival is based on tumor 
stage and functional status are self-evident. Actual 5-year 
survival, however, is the standard used in the oncology 
literature and is 69% for stage I disease in this series 
rather than the 93% disease-related survival reported. 
Five-year survival was 0% in patients with stage II disease, 
18% in those with stage IIIA, and 0% in both stage IIIB 
and stage IV disease. Clinical staging with computed 
tomographic scanning has a sensitivity and specificity of 
only 65%. Therefore, how confident are you that a 
significant number of these patients were not both over- 
staged and understaged, potentially confounding not only 
your decision-making regarding operability but also your 
reported survival statistics? What were the reasons for 
inoperability in patients with stage I disease? Would 
bronchoplastic resections have been possible if a pneumo- 
nectomy was not feasible? Were patients with clinical 
stage IIIA disease denied consideration for operation on 
the basis of enlarged lymph nodes without mediastinos- 
copy? What is the role for PDT in treating early-stage lung 
cancers with curative intent? Do your data provide 
enough phase I/II feasibility information to provide the 
basis for a phase III trial in one of the national oncology 
groups? 
The compelling point from this presentation is that 
patients with endobronchial obstruction from advanced 
cancer still have a median survival of 7 months and 
deserve aggressive airway palliation to manage dyspnea, 
cough, and obstructive pneumonia. 
The authors report an average of three bronchoscopic 
treatments per patient under general anesthesia for the 
application of PDT. These patients also had mechanical 
debridement and dilatation, similar to the techniques that 
we have reported in more than 250 procedures for endo- 
bronchial obstruction at the University of Washington. 
What is the additional benefit of PDT over these cheaper 
and more readily available techniques? What equipment 
must one purchase and at what cost to provide PDT? 
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Finally, there are suggestions in the literature that 
photoporphyrins may also be a radiosensitizer. Is it safe to 
radiate these patients after injection with DHE, and could 
this potentially provide even greater oncologic results with 
selective radiosensitization f the primary and metastatic 
tumor? 
Dr. Joseph LoCieero I I I  (Boston, Mass.). We owe a debt 
of gratitude to Dr. McCaughan for his perseverance and 
persistence with a technique that has really been an 
orphan procedure for about 15 years. This particular 
approach, the drug and the therapy, now is approved by 
the Food and Drug Administration for treatment of 
esophageal cancer. The drug is now available. The cost for 
the hospital is $2000 per vial. It remains an expensive 
therapy. Dr. Wood mentioned the cost of the laser to go 
with this. Right now it runs about $100,000. This is not a 
particularly inexpensive therapy. However, there will be a 
trial for esophageal cancer, really for dysplasia in Barrett's 
esophagus, which will begin fairly soon. The drug will also 
be presented to the Food and Drug Administration for 
approval for treatment in lung cancer and will be available 
for that therapy most likely within the year. 
I have a question specifically for Dr. McCaughan, who 
has really been a light in the darkness. Are all of these 
bronchoscopic procedures performed with the patient 
under general anesthesia and does the patient need to stay 
in the hospital? When we compare this technique with our 
present herapies, is there going to be a cost advantage to 
this particular type of therapy? 
In our early experience using PDT, which is now about 
5 years old, we found an increased incidence of problems 
with lung damage in patients who received radiation 
therapy afterward. Trying to produce an animal model or 
even a test-tube model to show that there has been 
increased sensitivity of these cells has been difficult. Do 
you have any experience to help us with that approach? 
Dr. MeCaughan. We treat these patients with x-ray 
therapy if they have not had it within a week or two after 
the treatment. We have had no increased problems from 
the radiotherapy. 
With regard to the staging, clinical staging is almost 
worthless, but it is the best thing we have. It never agrees 
with pathologic staging. It does supply all the statistics, 
which can be compared. 
The problem with doing survival curves is that these are 
elderly patients who die of other diseases. If you operated 
on 100 patients and put them in an airplane a week later 
and they all crashed and died, you would not say that your 
survival was 1 week. You have to take into account hat 
these patients have other problems, and that is what the 
standard Kaplan-Meier statistical curve does, the same as 
the actuarial curves. 
The decision was made by thoracic surgeons who 
referred the patients to us because they believed that 
these patients would not tolerate the operation because 
they already had surgery or their pulmonary functions 
were too poor. This was their decision. Because they were 
all in private practice, they were not particularly eager to 
give away patients. Most of the patients with stage I I IA 
disease had had chemotherapy and x-ray therapy. Many of 
them had had surgery. The usual litany is surgery, x-ray 
therapy, and chemotherapy. If that approach does not 
work, they are sent for PDT. Then we are asked, "Well, 
how many did you cure?" Obviously we started with 
poor-risk patients. If PDT can offer them the possibility of 
6 months' survival, it is worth trying. 
Notice of correction 
In the Apr i l  1997 issue of the Journal,  in the article by Benett i  and associates t it led "Minimal ly 
Invasive Aort ic  Valve Rep lacement"  (1997;113;806-7), an error was made.  Ines Benett i  was 
incorrectly identif ied as having an MD degree. 
